Sign In

Lawrence Andrews

Cancer Immunologist

Lawrence Andrews is a talented immunologist and postdoctoral research fellow, currently working at the University of Pittsburgh. He obtained his PhD in Immunology at the University of Southampton, where he also earned his Masters of Research in Cell Biology and Immunology of Cancer. With a Bachelor of Science in Biochemistry from the University of Warwick in hand, Lawrence has worked on projects at various renowned institutions throughout his academic career, including St. Jude Children's Research Hospital. He has also been involved in the Biotechnology Young Entrepreneur Scheme at BBSRC, where he gained valuable insight and experience.

Aside from his academic pursuits, Lawrence has held various leadership positions in both academic and professional contexts, including his previous roles as President and Academic Officer of the Life Sciences Postgraduate Society at the University of Southampton. He has also worked as a Brand Development Manager at Top Employers - Law and as a Student Associate with the Training and Development Agency for Schools.

With his diverse skill set and wealth of experience, Lawrence Andrews is poised to make a significant impact in the field of immunology and beyond.

Highlights

Aug 8 · linkedin

I’m happy to share with Samuel Butler in Dario Vignali's lab, our paper describing mechanistic insights into the synergistic interplay between LAG-3 and PD-1 on CD8+ T cells, driving exhaustion to ultimately hinder anti-tumor immunity. A story involving NKG2A as a clonal attribute that is lost with LAG3 and PD1 deficiency promoting TCR diversity and the requirement for autocrine IFN-gamma signaling to maintain optimal anti-tumor immunity.

Thanks to all who have contributed – this work is part of a trio of papers published today in Cell (Cell by Cell Press) with Anthony Cillo showing metastatic melanoma patients treated with relatlimab (anti-LAG-3) and nivolumab (anti-PD1) [Opdualag] exhibit enhanced TCR signaling and effector function through similar mechanisms and Shin Foong Ngiow from E. John Wherry's lab using the LCMV clone 13 model to assess the synergistic contribution of LAG-3 and PD-1.

Related Questions

What are Lawrence Andrews' main research interests at Arcellx?
How did Lawrence Andrews transition from the University of Pittsburgh to Arcellx?
What are some notable achievements of Lawrence Andrews in the field of immunotherapy?
Can you provide more details about the studies led by Lawrence Andrews at Arcellx?
What is Lawrence Andrews' educational background and how has it influenced his career?
Lawrence Andrews
Lawrence Andrews, photo 1
Lawrence Andrews, photo 2
Add to my network

Location

Washington DC-Baltimore Area